[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"ProMedica Health System\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":105},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100620335","phase-3-emergent-large-vessel-occlusion-endovascular-rescue-therapy-with-underlying-intracranial-stenosis-100620335",false,"NCT07356284","Emergent Large Vessel Occlusion Endovascular Rescue Therapy With Underlying Intracranial Stenosis","EVEREST","Inclusion Criteria:\n\n1. 18 to 80 years of age\n2. Presenting with symptoms consistent with AIS\n3. Imaging evidence of an anterior occlusion of the Internal Carotid Artery (ICA) or Middle Cerebral Artery Main Stem (MCA M1), or proximal M2 segment AND residual 70-99% stenosis of the index artery following attempted clot retrieval with either aspiration catheters or stent retrievers, per device instructions for use and device labeling\n4. NIHSS ≥ 6\n5. Ability to randomize within 24 hours of stroke onset.\n6. Pre-stroke mRS score 0-2\n7. Ability to obtain signed informed consent.\n8. ASPECTS Score ≥ 6 by non-contrast CT scan\n9. Score-ICAD score of ≥11 points at screening and\u002For persistent stenotic occlusion of ≥70% after MT\n10. If indicated, thrombolytic therapy shall be initiated per the institution's usual care and the most recent version of the AHA\u002FASA Guidelines. Subjects eligible for IV thrombolysis should receive it without delay.\n11. For subjects presenting \\>6 hours from stroke onset, infarct core volume \\\u003C50 cc quantified by CTP\n\nExclusion Criteria:\n\n1. Females who are pregnant, or those of child-bearing potential with positive urine or serum beta Human Chorionic Gonadotropin (HCG) test\n2. Known severe allergy (more than a rash) to contrast media uncontrolled by medications.\n3. CT evidence of the following conditions:\n\n   * Midline shift or herniation\n   * Evidence of intracranial hemorrhage\n   * Mass effect with effacement of the ventricles\n4. Acute bilateral strokes\n5. Contraindication to antiplatelet (aspirin, clopidogrel, ticagrelor, cangrelor) or contrast agents\n6. Intracranial tumors other than small meningioma, that do not require surgery for at least one year post randomization. Small meningioma is defined as a lesion measuring ≤20mm in maximum diameter or ≤4cm3 in volume, with no associated mass effect, peritumoral edema, or progressive neurological symptoms\n7. Known hemorrhagic diathesis, coagulation factor deficiency, or on anticoagulant therapy with an International Normalized Ratio (INR) of \\>3.0 or Partial Thromboplastin Time (PTT) \\>3 times of normal\n8. Baseline platelet count \\\u003C80,000 per microliter (µl)\n9. Life expectancy less than one year prior to stroke onset\n10. Participation in another randomized clinical trial that could confound the evaluation of the study outcomes.\n11. Any other condition (in the opinion of the site investigator) that precludes an endovascular procedure or poses a significant hazard to the patient if an endovascular procedure was performed\n12. New diagnosis of atrial fibrillation or a history of atrial fibrillation\n13. Suspected device-induced vasospasm defined as smooth transient narrowing of the target vessel\n14. Vessel dissection including any of the following: presence of dissection flap, false lumen, contrast stagnation in the vessel wall, and\u002For improving stenosis\n\n    \\-","ALL","18 Years","80 Years",{"count":20,"type":21},342,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The study objective is to establish the safety and efficacy of endovascular adjunct stenting for patients undergoing mechanical thrombectomy (MT) that are found to have residual stenosis (70-99%) following attempted clot retrieval with either aspiration catheters or stent retrievers, per device instructions for use and device labeling.",[27,28,29],"Brain Stroke","Stenting Treatment","Acute Ischemic Stroke",[31,32],"mechanical thrombectomy","Acute Ischemic stroke","RECRUITING","2026-05-20",{"date":36,"type":37},"2026-05-22","ACTUAL",{"date":39,"type":37},"2026-05-19",{"date":41,"type":21},"2030-06-01",{"name":43,"class":44},"ProMedica Health System","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":45},"100589039","phase-2-adjunctive-intra-arterial-tenecteplase-following-mechanical-thrombectomy-ally-ii-trial-100589039","NCT06949228","Adjunctive Intra-arterial Tenecteplase Following Mechanical Thrombectomy (ALLY) II Trial","ALLY II TNK","Inclusion Criteria:\n\n1. Age 18-85\n2. Anterior circulation ischemic stroke symptoms with confirmed occlusion (ICA, M1, or M2) on angiogram and mechanical thrombectomy initiated within 24 hours since last known well\n3. Alberta Stroke Program Early CT Score (ASPECTS) Score ≥6 on baseline Non-contrast Head CT (NCCT)\n4. Post-mechanical thrombectomy with ≤5 device passes and mTICI grade 2b or higher.\n5. Ability to obtain signed informed consent prior to randomization from LAR or Subject\n\nExclusion Criteria:\n\n1. Premorbid modified Rankin scale (mRS) score \\>1\n2. Imaging evidence of hemorrhage or mass effect at baseline\n3. Platelet count \\\u003C100,000\n4. Active hemorrhagic diathesis, or known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency\n5. Active anticoagulation treatment with novel oral anticoagulant (NOACs) taken within the last 48 hours, or INR \\>1.7\n6. Patients requiring active treatment with dual antiplatelet agents (e.g. proximal cervical carotid artery stenting)\n7. Pregnant or lactating\n8. Previous known allergy to TNK\n9. Major surgery in past 30 days\n10. Patient is on or requires dialysis\n11. History of intracranial hemorrhage or serious head trauma at any time\n12. Any condition in the opinion of the enrolling physician that would preclude the patient from participating\n13. Pre-existing medical, neurological, or psychiatric disease that would confound the neurological or functional evaluation\n14. Severe, uncontrolled hypertension (systolic blood pressure \\>180 mmHg or diastolic blood pressure \\>110 mmHg) that is refractory to treatment\n15. History of acute ischemic stroke in the last 60 days and\u002For has received previous treatment with a thrombolytic within the last 90 days\n16. Presumed septic embolus; suspicion of bacterial endocarditis\n17. Suspicion of aortic dissection\n18. Intracranial neoplasm\n19. Any terminal medical condition with life expectancy less than 6 months\n20. Concurrent enrollment in another trial that could confound the results of this study\n21. Patient is unlikely to return for 90-day follow-up.\n22. Intravenous tissue plasminogen activator (tPA) administered concurrently with Intra-arterial TNK","85 Years",{"count":55,"type":21},132,[57,24],"PHASE2","The study objective is to evaluate the safety and efficacy of Intra arterial (IA) Tenecteplase (TNK) as an adjunctive therapy in acute ischemic stroke (AIS) patients with large vessel occlusions (LVO) in the anterior circulation of Internal Carotid Artery (ICA), Middle Cerebral Arteries (M1 and M2) who achieve a reperfusion grade of Modified Treatment in Cerebral Ischemia Scale (mTICI) 2b or higher post-mechanical thrombectomy using Food and Drug Administration (FDA) approved devices.",[60,61],"Ischemic Stroke","Acute Disease",[63,64,65],"Stroke","TNK","Thrombolytic","2026-01-20",{"date":68,"type":37},"2026-01-21",{"date":70,"type":37},"2025-07-30",{"date":72,"type":21},"2028-05-30",{"name":43,"class":44},{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":85,"conditions":86,"keywords":90,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":4},"100587350","use-of-the-pteye-device-to-reduce-inadvertent-parathyroidectomy-during-thyroid-surgery-100587350","NCT06927245","Use of the PTEye Device to Reduce Inadvertent Parathyroidectomy During Thyroid Surgery","Use of Intraoperative Autofluorescence Imaging to Reduce the Incidence of Inadvertent Parathyroidectomy During Thyroid Surgery","Inclusion Criteria:\n\n* Patients undergoing either a total thyroidectomy or a thyroid lobectomy\n* Patients must be 18 years old or older\n* Patient needs to be operated on by a study approved surgeon\n\nExclusion Criteria:\n\n* Under 18 years old\n* Receiving a planned parathyroidectomy, Cistrunk procedure, repeat neck surgery, or neck dissection\n* Receiving surgery from a non-approved surgeon\n* Pregnant at time of procedure",{"count":82,"type":21},25,[84],"NA","Inadvertent Parathyroidectomy (IP) during thyroid surgery may lead to transient or permanent hypoparathyroidism and hypocalcemia, which represents significant morbidity. Patients that suffer from IP and its clinical consequences often require longer duration of hospitalization and additional inpatient treatment and prescription medications. ProMedica performs a large number of endocrine procedures, so the use of novel technology to aid in the intra operative identification of parathyroid glands may ultimately offer decreased morbidity to patients.\n\nThe goal of this study is to find out if using the PTEye device (a device that uses infrared light to find the Parathyroid gland) lowers the amount of times a surgeon accidentally takes out the Parathyroid gland while trying to take out the Thyroid gland in surgery.",[87,88,89],"Thyroid Surgery","Inadvertent Parathyroidectomy","Enlarged Thyroid",[91,92,93,94,88,95],"PTEye","Total Thyroidectomy","Thyroid Lobectomy","Intraoperative Autofluorescence Imaging","Inadvertent Parathyroid Removal","NOT_YET_RECRUITING","2025-08-05",{"date":99,"type":37},"2025-08-11",{"date":101,"type":21},"2025-09-01",{"date":103,"type":21},"2025-12-31",{"name":43,"class":44},""]